이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Apellis Pharmaceuticals 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Cedric Francois
최고 경영자
US$10.4m
총 보상
CEO 급여 비율 | 7.1% |
CEO 임기 | 15yrs |
CEO 소유권 | 1.5% |
경영진 평균 재임 기간 | 5.6yrs |
이사회 평균 재임 기간 | 9.2yrs |
최근 관리 업데이트
Recent updates
Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates
Nov 09Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise
Sep 28CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$333m |
Mar 31 2024 | n/a | n/a | -US$417m |
Dec 31 2023 | US$10m | US$735k | -US$529m |
Sep 30 2023 | n/a | n/a | -US$606m |
Jun 30 2023 | n/a | n/a | -US$657m |
Mar 31 2023 | n/a | n/a | -US$691m |
Dec 31 2022 | US$9m | US$681k | -US$652m |
Sep 30 2022 | n/a | n/a | -US$634m |
Jun 30 2022 | n/a | n/a | -US$638m |
Mar 31 2022 | n/a | n/a | -US$702m |
Dec 31 2021 | US$9m | US$647k | -US$746m |
Sep 30 2021 | n/a | n/a | -US$520m |
Jun 30 2021 | n/a | n/a | -US$460m |
Mar 31 2021 | n/a | n/a | -US$360m |
Dec 31 2020 | US$9m | US$619k | -US$345m |
Sep 30 2020 | n/a | n/a | -US$536m |
Jun 30 2020 | n/a | n/a | -US$470m |
Mar 31 2020 | n/a | n/a | -US$423m |
Dec 31 2019 | US$4m | US$560k | -US$305m |
Sep 30 2019 | n/a | n/a | -US$228m |
Jun 30 2019 | n/a | n/a | -US$194m |
Mar 31 2019 | n/a | n/a | -US$156m |
Dec 31 2018 | US$4m | US$550k | -US$128m |
Sep 30 2018 | n/a | n/a | -US$109m |
Jun 30 2018 | n/a | n/a | -US$85m |
Mar 31 2018 | n/a | n/a | -US$64m |
Dec 31 2017 | US$2m | US$400k | -US$51m |
보상 대 시장: Cedric 의 총 보상 ($USD 10.37M )은 US 시장( $USD 6.82M ).
보상과 수익: 회사가 수익성이 없는 동안 Cedric 의 보상이 증가했습니다.
CEO
Cedric Francois (52 yo)
15yrs
테뉴어
US$10,373,049
보상
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
Co-Founder | 15yrs | US$10.37m | 1.51% $ 54.1m | |
Co-Founder & Director | 15.7yrs | US$495.96k | 0.64% $ 22.9m | |
CFO & Treasurer | 6.9yrs | US$3.74m | 0.084% $ 3.0m | |
Chief Operating Officer | less than a year | US$3.71m | 0.023% $ 832.5k | |
General Counsel | 10.7yrs | US$4.89m | 0.094% $ 3.4m | |
Chief Medical Officer | 1.7yrs | US$4.43m | 0.0052% $ 184.8k | |
Co-Founder & Chief Scientific Officer | 15yrs | US$3.08m | 0.91% $ 32.8m | |
VP, Corporate Controller & Chief Accounting Officer | 3.1yrs | 데이터 없음 | 0.010% $ 357.1k | |
Senior Vice President | no data | 데이터 없음 | 데이터 없음 | |
Chief People Officer | 4.3yrs | 데이터 없음 | 0.00073% $ 26.2k | |
Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 2.3yrs | 데이터 없음 | 데이터 없음 | |
Senior Vice President | 5.6yrs | 데이터 없음 | 0.0031% $ 110.9k |
5.6yrs
평균 재임 기간
51.5yo
평균 연령
경험이 풍부한 관리: APLS 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.
이사회 구성원
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
Co-Founder | 15yrs | US$10.37m | 1.51% $ 54.1m | |
Co-Founder & Director | 15yrs | US$495.96k | 0.64% $ 22.9m | |
Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
Independent Chairman of the Board | 11.2yrs | US$504.08k | 0.00056% $ 20.1k | |
Independent Director | 11.2yrs | US$488.46k | 0.00056% $ 20.1k | |
Member of AMD Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
Member of PNH Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
Member of Pulmonology Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 | |
Independent Director | 4.4yrs | US$489.08k | 0.0047% $ 167.2k | |
Independent Director | 14.5yrs | US$480.96k | 0.12% $ 4.3m | |
Member of Pulmonology Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
Member of Pulmonology Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 |
9.2yrs
평균 재임 기간
57.5yo
평균 연령
경험이 풍부한 이사회: APLS 의 이사회는 경험(평균 재직 기간 9.1 년)으로 간주됩니다.